Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motexafin gadolinium

Drug Profile

Motexafin gadolinium

Alternative Names: API-GP3; FP-GP1; Gadolinium (III) texaphyrin; Gadolinium texaphyrin; Gd-Tex; Gd-texaphyrin; GdT2B2; MGd; PCI-0120; Xcytrin

Latest Information Update: 15 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacyclics
  • Class Antineoplastics; Lanthanoid series elements; Metallotexaphyrins; Small molecules
  • Mechanism of Action Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Brain cancer; Cardiovascular disorders; Chronic lymphocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2014 Pharmacyclics terminates a phase II trial in Chronic lymphocytic leukaemia and small lymphocytic lymphoma in USA (NCT00100711)
  • 13 Jun 2008 Final efficacy data from a phase I/II trial in non-Hodgkin's lymphoma released by Pharmacyclics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top